PracticeUpdate Conference Series: IID 2018

PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. Editor-in-Chief Robert T Brodell MD, FAAD Associate Editors Ashish C Bhatia MD, FAAD Eliot Mostow MD, MPH Advisory Board Sarah L Chamlin MD Jane Grant-Kels MD Christen Mowad MD Editorial Contributors InYoung Kim MD, PhD , Caitlyn Reed MD Jeffrey Scott MD, Anna Wile MD

PracticeUpdate ® is a registered trademark of Elsevier Inc. 2018 Elsevier Inc. All rights reserved. ABOUT

For a complete listing of disclosures for each board member and editorial contributor, please refer to their profile on PracticeUpdate.com PracticeUpdate ’s mission is to help medical professionals navigate the vast array of available literature and focus on the most critical information for their patients and practice. PracticeUpdate Conference Series is a collection of key research from leading international conferences, reviewed by the PracticeUpdate editorial and advisory board, made available in print format. These news highlights and more are also available online at PracticeUpdate.com PracticeUpdate and the PracticeUpdate Conference Series are commercially supported by advertising, sponsorship, and educational grants. Individual access to PracticeUpdate.com is free. Premium content is available to any user who registers with the site. While PracticeUpdate is a commercially-sponsored product, it maintains the highest level of academic rigour, objectivity, and fair balance associated with all Elsevier products. No editorial content is influenced in any way by commercial sponsors or content contributors. DISCLAIMER The PracticeUpdate Conference Series provides highlights of key international conferences for specialist medical professionals. The ideas and opinions expressed in this publication do not necessarily reflect those of the Publisher. Elsevier will not assume responsibility for damages, loss, or claims of any kind arising from or related to the informationcontained in thispublication, includinganyclaimsrelated to the products, drugs, or services mentioned herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Please consult the full current Product Information before prescribing any medication mentioned in this publication. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. The production and distribution of this publication is sponsored by Sanofi Genzyme. It contains content published in accordance with the editorial policies of Elsevier’s PracticeUpdate.com. Content was produced by Elsevier with no involvement by Sanofi Genzyme. All content printed in this publication can be found on PracticeUpdate.com SALES Fleur Gill fleur.gill@elsevier.com Linnea Mitchell-Taverner l.mitchell@elsevier.com PRODUCTION Content was originally published on PracticeUpdate.com Production of this issue was executed by: Editorial Manager A nne Neilson anne.neilson@elsevier.com Editorial Project Manager Carolyn Ng Designer Jana Sokolovskaja Cover: Immunoglobulin G antibody molecule/gettyimages.com ISSN 2208-150X (Print) • ISSN 2208-1518 (Online)

Courtesy of IID 2018

Contents

IID 2018 • 16–19 May 2018 • Orlando, Florida, USA BY THE PRACTICEUPDATE EDITORIAL TEAM

4

14

4 Results of Two Studies Point to Potential Treatments for Alopecia Areata 6 Cutaneous Bacterial Presence May Provoke Activated Immune Response in Hidradenitis Suppurativa 8 The OX40 Inhibitor GBR 830 Induces Progressive and Sustained Changes in Biomarkers of Eczema 9 Results of Two Preclinical Studies Point to Potential Therapeutic Targets in Cutaneous T-Cell Lymphoma 10 Neutralization of Interleukin 17 Implicated in Inflammatory Skin Diseases Overall and in Psoriasis Specifically 12 CD8-Positive T Cells Predict Disease Progression and Drive Visible Inflammation in Cutaneous T-Cell Lymphoma

14 BLZ-100 (Tozuleristide) Shown to Discriminate Between Subtle Molecular Subtypes of Basal Cell Carcinoma 14 Secukinumab Reduces CD4-Positive Th17, As Well As CD8- and CD4-Positive Treg Cells in Patients With Plaque Psoriasis 16 Vitamin C and Its Derivatives Suppress Melanogenesis 18 Results of Two Studies Point to Janus Kinase Inhibition for Alopecia Areata 18 After 52 Weeks, Ixekizumab Is Linked to Consistently Higher Responses Than Ustekinumab Across Patient Subgroups With Moderate to Severe Plaque Psoriasis 20 Response to IL-23 Blockade With Guselkumab Associated With HLA-Cw6 Status in Patients With Psoriasis 22 Two Topical Preparations Show Promise for Eczema

ELSEVIER AUSTRALIA ABN 70 001 002 357 475 Victoria Avenue Chatswood NSW 2067 Australia Locked Bag 7500 Chatswood DC NSW 2067 Printed in Australia. EMCS061803

3

IID 2018 • PRACTICEUPDATE CONFERENCE SERIES